Key Takeaways
- • Sound Wave Innovation raised ¥2.65 billion ($16.7–$17.5 million) in Series C funding led by iGlobe Partners to advance clinical development of low-intensity pulsed ultrasound (LIPUS) therapy for Alzheimer's disease.
- • The funding will support an ongoing clinical trial scheduled for completion by end of year, addressing a critical gap in early-stage Alzheimer's treatment options.
- • Sound Wave Innovation has secured a strategic partnership with Sumitomo Heavy Industries, a major Japanese industrial conglomerate, to scale manufacturing and commercialization of the LIPUS-Brain device.
- • The company is developing a non-pharmacological, device-based approach to Alzheimer's treatment, positioning itself in a competitive therapeutic landscape alongside monoclonal antibody treatments and emerging peptide therapies.
- • The funding round reflects strong institutional investor appetite for innovative medical device solutions targeting neurodegenerative disease, particularly in Japan's aging demographic context.
Summary
Sound Wave Innovation, a Tokyo-based medical device startup, announced the completion of a Series C funding round totaling ¥2.65 billion (approximately $16.7–$17.5 million) on May 18, 2026. The round was led by iGlobe Partners and marks a significant capital injection to accelerate the company's clinical and commercial development pipeline for Alzheimer's disease treatment.
The capital will directly fund an ongoing clinical trial of Sound Wave's proprietary low-intensity pulsed ultrasound (LIPUS) therapy, with trial completion expected by year-end. LIPUS represents a device-based, non-pharmacological approach to early-stage Alzheimer's treatment, differentiating the company from antibody-based therapeutics currently dominating the market. The therapy utilizes ultrasound technology to target neuroinflammation and cognitive decline, addressing an unmet clinical need in early disease intervention.
Beyond capital infusion, Sound Wave has formalized a strategic partnership with Sumitomo Heavy Industries, one of Japan's largest industrial manufacturers. This partnership is expected to accelerate the development and commercialization of Sound Wave's LIPUS-Brain device, leveraging Sumitomo's manufacturing expertise, regulatory relationships, and distribution capabilities. The collaboration underscores institutional confidence in the technology's viability and commercial potential.
The funding environment for Alzheimer's therapeutics remains robust, with multiple funding mechanisms—venture capital, strategic partnerships, and device-focused investors—actively supporting innovation in neurodegenerative disease. Sound Wave's successful raise occurs amid broader Japanese startup momentum in deep tech and medical innovation, reflecting investor confidence in both the company's technology platform and Japan's aging society as a critical market for neurological treatments.
The capital will directly fund an ongoing clinical trial of Sound Wave's proprietary low-intensity pulsed ultrasound (LIPUS) therapy, with trial completion expected by year-end. LIPUS represents a device-based, non-pharmacological approach to early-stage Alzheimer's treatment, differentiating the company from antibody-based therapeutics currently dominating the market. The therapy utilizes ultrasound technology to target neuroinflammation and cognitive decline, addressing an unmet clinical need in early disease intervention.
Beyond capital infusion, Sound Wave has formalized a strategic partnership with Sumitomo Heavy Industries, one of Japan's largest industrial manufacturers. This partnership is expected to accelerate the development and commercialization of Sound Wave's LIPUS-Brain device, leveraging Sumitomo's manufacturing expertise, regulatory relationships, and distribution capabilities. The collaboration underscores institutional confidence in the technology's viability and commercial potential.
The funding environment for Alzheimer's therapeutics remains robust, with multiple funding mechanisms—venture capital, strategic partnerships, and device-focused investors—actively supporting innovation in neurodegenerative disease. Sound Wave's successful raise occurs amid broader Japanese startup momentum in deep tech and medical innovation, reflecting investor confidence in both the company's technology platform and Japan's aging society as a critical market for neurological treatments.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.